Dupilumab, a fully human, monoclonal antibody inhibiting signaling of both interleukin (IL)‐4 and IL‐13 is the first and only targeted biologic treatment approved for moderate to severe AD until now.2 This evidence concerns the gene IL13 and Alzheimer disease.